Fosfa

Solid tumours including the cervix, lung, ovary, testis & thymus, as well as in sarcoma. Lymphomas.

Dosage regimen: Total dose of 8-12 g/m² divided over 3-5 days w/ the course repeated at 2-4 wk intervals; total dose of 6 g/m² divided over 5 days, repeated every 3 wk; & doses of 5 to 6 g/m² to a max of 10 g as a single 24-hr infusion, repeated at 3-4 wk interval. The interval between courses also depends on the blood count.

Hypersensitivity. Urinary outflow obstruction.

Exclude or correct any obstruction of efferent urinary tract, cystitis, infections & electrolyte imbalance prior to treatment. Strictly recommended to refrain vaccinations after treatment. Neurologic manifestations eg, somnolence, confusion, hallucinations & coma. Patients w/ leukopenia, thrombocytopenia, tumour cell infiltration of bone marrow, prior RT or treatment w/ other antineoplastic agents or nephrotoxic drugs (eg, cisplatin), brain metastases & advanced cerebral arteriosclerosis, impaired renal/hepatic function, known infections &/or abnormal serum creatinine & albumin levels; who develop fungal or viral infections; chicken pox, herpes zoster, infection, kidney/liver disease. Possibility or potential of oncogenic activity. Nausea & vomiting may occur. Report unusual bleeding or bruising, black tarry stools, blood in urine or stools & pinpoint red spots on the skin. Should not be initiated for at least 10-14 days after surgery or until 3 mth after nephrectomy. Ensure vigorous oral or parenteral hydration. Urotoxic side effects especially hemorrhagic cystitis. W/hold subsequent administration if microscopic hematuria (>10 RBCs per high power field). Obtain urinalysis; WBC, platelet count & Hb prior to each administration & at appropriate intervals. Monitor hematologic profile (neutrophils, platelets) & urine regularly. Concomitant use w/ other chemotherapeutic drugs; steroids; amphotericin B inj, anti-thyroid agents, azathioprine, chloramphenicol, colchicine, flucytosine, ganciclovir, interferon, plicamycin, zidovudine &/or treatment w/ x-rays or other cancer medicines. Pregnancy & lactation. Childn.

Confusion, drowsiness, depressive psychosis, hallucinations.

Increased metabolism w/ CYP3A4 inducers (eg, carbamazepine, phenytoin, fosphenytoin, phenobarb, rifampin, St. John's wort) & decreased w/ CYP3A4 inhibitors (eg, ketoconazole, fluconazole, itraconazole, sorafenib, aprepitant, fosaprepitant, grapefruit, grapefruit juice). May increase formation of neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde w/ CYP3A4 inducers.

Cytotoxic Chemotherapy

L01AA06 - ifosfamide ; Belongs to the class of alkylating agents, nitrogen mustard analogues. Used in the treatment of cancer.

Rx